首页> 外文OA文献 >Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

【2h】

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

机译：II型甘油型人源化抗CD20单克隆抗体ObInutuzumab（Ga101）的第1次研究结果在B细胞淋巴瘤患者中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

AI期刊论文写作 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Gilles Salles; Franck Morschhauser; Thierry Lamy; Noel Milpied; Catherine Thieblemont; Hervé Tilly; Gabi Bieska; Elina Asikanius; David Carlile; Joe Birkett; Pavel Pisa; Guillaume Cartron;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 复发性晚期滤泡性淋巴瘤的IDEC-C2B8(利妥希玛)抗CD20抗体治疗:德国低度恶性淋巴瘤研究组Ⅱ期研究结果 [J] . 李登举, 唐锦治中德临床肿瘤学杂志（英文版） . 2001,第004期
2. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients [J] . SallesG., MorschhauserF., LamyT., Blood: The Journal of the American Society of Hematology . 2012,第22期

机译：II型糖工程化人源化抗CD20单克隆抗体obinutuzumab（GA101）在B细胞淋巴瘤患者中的1期研究结果
3. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies [J] . Tobinai Kensei, Klein Christian, Oya Naoko, Advances in therapy. . 2017,第2期

机译：对obInutuzumab（Ga101）的综述，一种新型II型抗CD20单克隆抗体，用于治疗B细胞恶性肿瘤患者
4. Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody [J] . Goede Valentin, Klein Christian, Stilgenbauer Stephan Oncology research and treatment. . 2015,第4期

机译：Obinutuzumab（GA101）用于治疗慢性淋巴细胞性白血病和其他B细胞非霍奇金淋巴瘤：糖工程化II型CD20抗体
5. Deglycosylation Study of Murine IgG1, IgG2a, IgG2b, and Humanized IgG1 Monoclonal Antibodies [C] . Megan Ellis, John Lambert, Alexandru C. Lazar American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：鼠IgG1，IgG2a，IgG2b和人源化IgG1单克隆抗体的脱糖基化研究
6. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
7. A Review of Obinutuzumab (GA101) a Novel Type II Anti-CD20 Monoclonal Antibody for the Treatment of Patients with B-Cell Malignancies [O] . Kensei Tobinai, Christian Klein, Naoko Oya, -1

机译：新型II型抗CD20单克隆抗体Obinutuzumab（GA101）的综述用于治疗B细胞恶性肿瘤
8. 895P Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin’s lymphoma [O] . Y-K. Shi, Y. Song, Y. Qin, 2020

机译：895P期I型研究结果II型甘油型抗CD20单克隆抗体MIL62中的复发/难治性CD20阳性B细胞非霍奇金淋巴瘤

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

著录项

引文网络

相似文献

相关主题

期刊订阅